Health Catalyst Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Portfolio Pulse from Benzinga Insights
Health Catalyst (NASDAQ: HCAT) has received mixed analyst ratings over the past three months, with 1 bullish and 3 somewhat bullish ratings. The average 12-month price target is $13.5, with a high of $16.00 and a low of $11.00. Recent analyst actions include Piper Sandler and Wells Fargo lowering their price targets, while Canaccord Genuity and Cantor Fitzgerald maintained their ratings.
June 06, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Health Catalyst has received mixed analyst ratings with 1 bullish and 3 somewhat bullish ratings over the past three months. The average 12-month price target is $13.5, slightly up from the previous $13.33. Piper Sandler and Wells Fargo have lowered their price targets, while Canaccord Genuity and Cantor Fitzgerald maintained their ratings.
The mixed analyst ratings and slight increase in the average price target suggest a neutral short-term impact on Health Catalyst's stock. The lowering of price targets by Piper Sandler and Wells Fargo is balanced by the maintained ratings from Canaccord Genuity and Cantor Fitzgerald.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100